252 related articles for article (PubMed ID: 8467803)
1. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.
McWhirter JR; Wang JY
EMBO J; 1993 Apr; 12(4):1533-46. PubMed ID: 8467803
[TBL] [Abstract][Full Text] [Related]
2. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.
McWhirter JR; Wang JY
Mol Cell Biol; 1991 Mar; 11(3):1553-65. PubMed ID: 1705008
[TBL] [Abstract][Full Text] [Related]
3. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
McWhirter JR; Galasso DL; Wang JY
Mol Cell Biol; 1993 Dec; 13(12):7587-95. PubMed ID: 8246975
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
Pendergast AM; Quilliam LA; Cripe LD; Bassing CH; Dai Z; Li N; Batzer A; Rabun KM; Der CJ; Schlessinger J
Cell; 1993 Oct; 75(1):175-85. PubMed ID: 8402896
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
[TBL] [Abstract][Full Text] [Related]
6. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein.
McWhirter JR; Wang JY
Oncogene; 1997 Oct; 15(14):1625-34. PubMed ID: 9349495
[TBL] [Abstract][Full Text] [Related]
7. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Gishizky ML; Cortez D; Pendergast AM
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
[TBL] [Abstract][Full Text] [Related]
8. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
[TBL] [Abstract][Full Text] [Related]
9. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
Muller AJ; Young JC; Pendergast AM; Pondel M; Landau NR; Littman DR; Witte ON
Mol Cell Biol; 1991 Apr; 11(4):1785-92. PubMed ID: 2005881
[TBL] [Abstract][Full Text] [Related]
10. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
[TBL] [Abstract][Full Text] [Related]
11. Molecular biology of chronic myeloid leukemia.
Maru Y
Int J Hematol; 2001 Apr; 73(3):308-22. PubMed ID: 11345196
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
Ren SY; Xue F; Feng J; Skorski T
Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
[TBL] [Abstract][Full Text] [Related]
13. The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation.
Renshaw MW; McWhirter JR; Wang JY
Mol Cell Biol; 1995 Mar; 15(3):1286-93. PubMed ID: 7862122
[TBL] [Abstract][Full Text] [Related]
14. Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family.
Reuther GW; Fu H; Cripe LD; Collier RJ; Pendergast AM
Science; 1994 Oct; 266(5182):129-33. PubMed ID: 7939633
[TBL] [Abstract][Full Text] [Related]
15. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
Arlinghaus RB
Oncogene; 2002 Dec; 21(56):8560-7. PubMed ID: 12476302
[TBL] [Abstract][Full Text] [Related]
16. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.
Guo XY; Cuillerot JM; Wang T; Wu Y; Arlinghaus R; Claxton D; Bachier C; Greenberger J; Colombowala I; Deisseroth AB
Oncogene; 1998 Aug; 17(7):825-33. PubMed ID: 9779999
[TBL] [Abstract][Full Text] [Related]
17. Philadelphia chromosome-positive leukaemia: the translocated genes and their gene products.
Allen PB; Morgan GJ; Wiedemann LM
Baillieres Clin Haematol; 1992 Oct; 5(4):897-930. PubMed ID: 1308169
[TBL] [Abstract][Full Text] [Related]
18. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
Campbell ML; Li W; Arlinghaus RB
Oncogene; 1990 May; 5(5):773-6. PubMed ID: 2140598
[TBL] [Abstract][Full Text] [Related]
19. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
